Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 28, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive...